

GBS History, Meningococcal Vaccination

BY SHARON WORCESTER

FROM A MEETING OF THE CDC'S ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES

ATLANTA — The Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices voted at its June meeting to remove language from its meningococcal vaccine statement warning that a history of Guillain-Barré syndrome should be considered a "precaution" to administering meningococcal conjugate vaccines.

The action followed the presentation of final results of a study conducted at Harvard Medical School/Harvard Pilgrim Healthcare involving nearly 12.6 million individuals aged 11-21 years.

No cases of Guillain-Barré syndrome (GBS) occurred within 6 weeks of vaccination in any of the 1.4 million participants who received quadrivalent meningococcal conjugate vaccine (MCV4, Menactra) doses, Priscilla Vejentgas, Ph.D., of Harvard Medical School and the Harvard Pilgrim Health Care Institute, Boston, reported.

"This study provided no evidence of increased risk of GBS associated with MCV4," she said.

Concern over a link between meningococcal conjugate vaccines and GBS arose in 2006. In October of that year, the CDC published findings from the Vaccine Adverse Event Reporting System (VAERS) indicating that the observed rate of GBS within 6 weeks of vaccination appeared to be elevated among adolescents aged 15-19 years.

The passive VAERS reporting system thus generated a "signal" of a possible problem, which triggered a CDC investigation using the Vaccine Safety Datalink.

That investigation also found no link between MCV4 and increased risk of GBS.

On the recommendation of the ACIP meningococcal working group, the committee voted to remove all precautionary language from the meningococcal statement, and background language will include relevant VAERS information and data from the studies showing no increased risk of GBS after meningococcal conjugate vaccine administration in the general population.

Additionally, the matter will be sent to the ACIP General Recommendations Working Group to address the risks and benefits of receiving any vaccine in a person with a history of postvaccine GBS. ■

Disclosures: Dr. Vejentgas said both Harvard Pilgrim Care and Outcome Sciences have accepted research funding from vaccine manufacturers, and that she is an employee of both. The study was funded by Sanofi Pasteur through a contract with Harvard Pilgrim.

Seasonal Flu Vaccine Recs for Kids Updated

BY SHARON WORCESTER

FROM A MEETING OF THE CDC'S ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES

ATLANTA — Children ages 6 months through 8 years who did not receive at least one dose of the 2009 influenza A(H1N1) monovalent vaccine during the 2009-2010 influenza season should receive two doses of a 2010-2011 seasonal influenza vaccine, which will include H1N1 coverage, according to a


new recommendation from the Centers for Disease Control and Prevention.

Prior recommendations stated that children in this age group who received two doses in the first influenza season in which they are vaccinated require only one dose the following season.

The CDC's Advisory Committee on Immunization Practices (ACIP) voted June 24 to make this change to its existing seasonal influenza vaccination recommendations.

The recommendations continue to state that children ages 6 months through 8 years who are receiving a seasonal vaccine for the first time should receive two doses, and that those who received only one dose of a seasonal vaccine in the first influenza season in which they were vaccinated should receive two doses in the following season.

If children in this age group received at least one dose of 2009 H1N1



DEXILANT WORKS A SECOND SHIFT TO HELP SHUT DOWN ACID PUMPS